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Abstract: Panic disorder (PD) is a disabling condition which appears in late adolescence or 
early adulthood and affects more frequently women than men. PD is frequently characterized 
by recurrences and sometimes by a chronic course and, therefore, most patients require long-
term treatments to achieve remission, to prevent relapse and to reduce the risks associated with 
comorbidity. Pharmacotherapy is one of the most effective treatments of PD. In this paper, 
the pharmacological management of PD is reviewed. Many questions about this effective 
treatment need to be answered by the clinician and discussed with the patients to improve 
her/his collaboration to the treatment plan: which is the drug of choice; when does the drug 
become active; which is the effective dose; how to manage the side effects; how to manage 
nonresponse; and how long does the treatment last. Moreover, the clinical use of medication in 
women during pregnancy and breastfeeding or in children and adolescents was reviewed and 
its risk-beneﬁ  t balance discussed.
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Introduction
Panic disorder (PD) (Table 1) is a disabling condition which exerts a negative impact on 
social, family and working lives of patients. PD is common in the general population, 
showing a one year prevalence of 2.7% and a life-time prevalence of 4.7% (Kessler, 
Berglund et al 2005; Kessler, Chiu et al 2005).
PD is consistently found to occur more frequently in females (twice more often 
in women than in men) (Eaton et al 1998; Kessler et al 1998) and to appear in late 
adolescence or early adulthood (Weissman et al 1997; Eaton et al 1998; Kessler et al 
1998). However, nearly half of adult patients report signiﬁ  cant difﬁ  culties with anxiety 
during childhood (Pollack 2005) and PD has frequently been diagnosed in clinically-
referred children and adolescents (10%) (Masi et al 2000).
PD is frequently associated with other mental disorders during life-time: mood 
disorders, in particular major depression (Kessler et al 1998; Simon and Fischmann 
2005), anxiety disorders, in particular agoraphobia (Goisman et al 1994), and alcohol 
abuse (Zimmermann et al 2003) are observed in many PD patients. Comorbid disorders 
may contribute to increase the severity of the illness, to be associated with suicide 
attempts, to reduce the response to treatment and to induce relapse (Lecrubier 1998; 
Slaap and den Boer 2001; Vickers and McNally 2004; Sareen et al 2005; Goodwin 
and Roy-Byrne 2006; Marchesi et al 2006a).
Also personality disorders, speciﬁ  cally those of the anxious cluster, are commonly 
observed in PD patients (Massion et al 2002; Grant et al 2005; Marchesi et al 2005). 
Personality disorders are supposed to increase the severity of symptoms (Ozkan et al 
2005), to predict the pattern of comorbidity, particularly the co-occurrence of major 
depression (Ampollini et al 1999; Ongur et al 2005; Ozkan et al 2005) and to have a 
negative inﬂ  uence on the response to treatment (Dreessen and Arntz 1998; Slaap and 
den Boer 2001; Marchesi, De Panﬁ  lis et al 2006).Neuropsychiatric Disease and Treatment 2008:4(1) 94
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The course of PD is variable: approximately one third 
of patients achieve remission, whereas one out of five 
follows an unremitting and chronic course (Rosenbaum et al 
1996; Katschnig and Amering 1998). Therefore, most of 
PD patients require long-term treatments (Davidson 1998; 
Doyle and Pollack 2004) and continuous evaluations to 
achieve remission, to prevent relapse and to reduce the risks 
associated with comorbidity.
Since PD mimics many life-threatening conditions (ie, 
cardiac or respiratory diseases) or is often associated with 
a catastrophic misinterpretation of physical sensations, 
PD induces a high use of medical services, particularly 
emergency departments (Katerndahl and Realini 1995; 
Ballenger 1997; Marchesi et al 2001; Marchesi et al 2004). 
Although, PD is frequently the reason for seeking treatment 
for medically unexplained symptoms (Kroenke 2003), it 
also increases the use of medical care when associated with 
medical illness and the risk of death in patients affected by 
coronary heart disease (Simon and Fischmann 2005).
Therefore, the identiﬁ  cation of this disorder and the 
appropriate treatment is essential to improve the quality of 
assistance and to reduce the waste of health care resources 
through unnecessary medical care. Educational efforts will 
ensure that effective treatments will be available for a greater 
number of patients.
The aim of this review is to provide clinicians with the 
useful information concerning the pharmacological treatment 
of PD, particularly the choice of medication, the management 
of non-responders, to decide when and how to discontinue 
treatment and to balance the risks and beneﬁ  ts in treating PD 
in women during pregnancy and breastfeeding.
Treatment
General considerations
Excluding medical disease
A careful history and physical examination are necessary for 
all patients to rule out medical causes of symptoms. Hyper-
thyroidism and hypothyroidism, pheochromocytoma, tem-
poral-lobe epilepsy, asthma, cardiac arrhythmias, excessive
intake of caffeine or other stimulants, withdrawal from 
alcohol, and treatment with high doses of corticosteroids can 
mimic or cause panic attacks.
Assessment of comorbidity
Particular attention should be paid in evaluating the presence 
of depressive symptoms in properly treated patients and to 
prevent the suicide risk, keeping in mind that depressed PD 
patients are less likely responders to treatment than non 
depressed subjects (Slaap and den Boer 2001; Marchesi 
et al 2006a).
Moreover, the use of alcohol as self-medication must be 
screened, the abuse should be prevented and the withdrawal 
symptoms should be properly treated. Finally, the evaluation 
of personality disorders is clinically useful, because these 
disorders may be associated with poor compliance and poor 
response to treatment (Slaap and den Boer 2001; Marchesi, 
De Panﬁ  lis et al 2006).
Education of patients and their families
Clinical experience suggests that patients and their families 
beneﬁ  t from education about PD as the cause of symptoms 
and about the mechanisms by which this disorder may 
provoke physical symptoms. In patients, this information 
Table 1  Diagnostic criteria for panic disorder, according to DSM-IV TR (APA 2000)
1.  Recurrent unexpected panic attacks*.
2.  At least one of the attacks has been followed by 1 month (or more) of one ( or more) of the following: 
  -  persistent concern about having additional attacks;
  -  worry about the implication of the attack or its consequences;
 -  a  signiﬁ  cant change in behaviour related to the attacks. 
3.  The panic attacks are not due to the direct physiological effects of a substance or a general medical condition.
4.   The panic attacks are not better accounted for by another mental disorder, such as social phobia, obsessive-compulsive disorder, posttraumatic 
stress disorder, or separation anxiety disorder.
* A discrete period of intense fear or discomfort, in which four (or more) of the following symptoms developed abruptly and reached a peak within 10 minutes: 
1.  palpitation, pounding heart, or accelerated heart rate;
2. sweating;
3.  trembling or shaking;
4.  sensation of shortness of breath or smothering;
5.  feeling of choking;
6.  chest pain or discomfort;
7.  nausea or abdominal distress;
8.  feeling dizzy, unsteady, lightheaded or faint;
9.  derealization or depersonalisation; 
10.  fear of loosing control or going crazy; 
11.  fear of dying. Neuropsychiatric Disease and Treatment 2008:4(1) 95
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may alleviate fears of having a serious condition, worries 
about the physical consequences of the attacks, and may 
convince families that the patient is affected by a disorder, 
thus avoiding the behavioral anger or rejection.
The outcome of treatment: response and remission
Panic attacks are the core feature of PD, yet other symp-
toms and functional impairment in daily life must be 
taken into account in evaluating the outcome of treat-
ment. Therefore, the assessment of limited symptom 
panic attacks, anticipatory anxiety, phobic avoidance and 
depression is fundamental during treatment and the clini-
cian must carefully monitor treatment to ensure that an 
optimal response is achieved.
However, no consensus exists regarding the standard 
criteria of response and remission, because there is no agree-
ment about symptom level resolution and the time frame 
to ensure stability. According to DSM-IV criteria, patients 
have been deﬁ  ned as “panic free” if they do not have a suf-
ﬁ  cient number of panic symptoms to meet the diagnostic 
criteria of PD. However, the “panic free” deﬁ  nition does 
not necessarily mean being free of all panic symptoms. 
In order to provide a frame of reference to clinicians, the 
International Consensus Group on Depression and Anxiety 
(ICGDA) (Ballenger et al 1998) suggests that the outcome of 
treatment should be evaluated in ﬁ  ve domains: panic attacks 
(including limited-symptom attacks), anticipatory anxiety, 
panic-related phobias, overall illness severity and disabili-
ties. The ICGDA deﬁ  nes: (1) “response” as a stable clinically 
signiﬁ  cant improvement of the full range of symptoms, but 
more than minimal symptoms continue to be present; and 
(2) “full remission” as the resolution of all ﬁ  ve domains of 
symptoms, maintained for a period of three months.
Even though the ICGDA recommends the careful 
evaluation and treatment of depression, it was not included in 
the criteria to deﬁ  ne response or remission. However, a few 
years later, the deﬁ  nition of PD remission also included the 
resolution of depressive symptoms (Ballenger 1999, 2001; 
Doyle and Pollack 2003).
However, in many clinical trials, the decrease of the 
frequency of panic attacks or global severity of anxiety 
has been used as primary efﬁ  cacy endpoints and has been 
evaluated over a short-term period (6–12 weeks) (den Boer 
1998; Mitte 2005).
Therefore, the conclusions about the efﬁ  cacy of treat-
ment drawn from the data of clinical trials can be extended 
to patients treated in clinical practice with some limitations, 
because these two populations show clinical differences. 
In fact, a higher rate of comorbidity, a more severe disorder 
and a lower level of compliance are frequently observed in 
patients treated in a clinical setting compared to patients 
enrolled in clinical trials. Moreover, most clinical trials 
provide a short-term evaluation of treatment, whereas PD 
patients require long-term treatment to achieve remission. 
Finally, the criteria of response often used in clinical trials 
(50% decrease in the frequency of panic attacks or global 
anxiety) (Mitte 2005) are associated with persistence of some 
anxious and depressive symptoms (Marchesi et al 2006a) and 
with an impairment in social functioning.
Clinicians and patients should be aware that PD requires 
long-term treatment to achieve remission, to prevent relapse 
and to reduce the risks associated with comorbidity.
Effective treatments
Currently, available clinical practice guidelines for the 
treatment of PD recommend pharmacotherapy or cognitive 
behavioral treatment (CBT), as effective treatments.
These recommendations have recently been conﬁ  rmed 
by a meta-analysis, comparing the efﬁ  cacy of CBT, phar-
macotherapy and placebo in PD (Mitte 2005). The meta-
analysis evaluated 53 studies of drug treatment (including 
a total of 7725 patients) and 43 studies of CBT (including 
1811 patients). Pharmacotherapy and CBT was superior to 
placebo, and showed a similar effect in alleviating anxiety, 
agoraphobia, depression and poor quality of life.
However, some differences exist among available guide-
lines regarding the recommended ﬁ  rst choice treatment:
1.   both the American Psychiatric Association (APA 1998) 
and the British Association for Psychopharmacology 
(BAP) (Baldwin et al 2005) recommend either phar-
macotherapy or CBT because “there is no convincing 
evidence that one modality is superior for all patients or 
for a particular subpopulation of patients” (APA 1998, 
p 2), and “drug and psychological treatments, delivered 
singly, have broadly similar efﬁ  cacy in acute treatment” 
(BAP 2005, p 580);
2.   the National Institute of Clinical Excellence (NICE 2004) 
recommends to consider that CBT has an effect that lasts 
longer than that of drugs;
3.   the Royal Australian and New Zealand College of Psy-
chiatry (RANZCP 2003) recommends CBT as “the most 
consistently efﬁ  cacious treatment” (p 645). This conclu-
sion has been also supported by the observation that 
CBT can “reduce the probability of relapse” (the same 
effect has not been demonstrated for pharmacotherapy) 
(p 644).Neuropsychiatric Disease and Treatment 2008:4(1) 96
Marchesi
Regardless of the differences among guidelines, patients 
and their families must be advised about the advantages and 
the disadvantages of these two effective treatments (Table 2), 
to provide them with the correct information necessary to 
participate in the decision regarding treatment.
Pharmacological treatment
Neurobiological bases
of the pharmacological effect
Consistent with the hypothesis that a dysfunction of brain 
pathways (Ninan and Dunlop 2005), using γ-aminobutyric 
acid (GABA (Zwanzger and Rupprecht 2005), serotonin 
(Maron and Shlik 2006) and noradrenaline (Neumeister et al 
2005) as neurotrasmitters, is involved in the pathogenesis of 
PD, the efﬁ  cacy of antipanic drugs is probably mediated by 
their effects on these neurochemical systems, even though 
their exact mechanism remains unclear.
The clinical strategies 
in pharmacotherapy
Once pharmacotherapy has been chosen, many questions 
about this effective treatment need to be answered by the 
clinician and discussed with the patients to improve his or her 
adherence to the plan of treatment; it is important to deter-
mine the drug of choice, to establish when the drug becomes 
active, what is the effective dose, how to manage side effects 
and non response, and the duration of treatment.
The choice of the drug
Efﬁ  cacy
Placebo effect
The placebo effect is a well-known phenomenon in the treat-
ment of PD. The percentage of patients who achieved a free 
from panic attacks status after placebo treatment ranged from 
14% to 59% in controlled clinical trials using SSRI, TCA or 
BDZ as active treatment (den Boer 1998). In a recent study 
(Khan et al 2005), the mean percentage of symptom improve-
ment was 50% in 1157 PD patients treated with placebo. 
Consequently, the aforementioned data suggest that a placebo 
plays an important role effect in short-term treatment of PD 
patients. However, the placebo effect disappears with time, and 
thus the available guidelines recommend the administration 
of medication that is more effective than placebo.
Effective medications
Four classes of drugs are more effective than placebo 
and showed similar efficacy in treating PD: tricyclic 
antidepressants (TCA), selective serotonin reuptake inhibi-
tors (SSRI), monoamine oxidase inhibitors (MAOI) and 
high-potency benzodiazepines (BDZ).
In a recent meta-analysis (Mitte 2005) the efficacy 
of TCA, SSRI and BDZ was compared: 53 studies were 
analyzed for a total of 7725 patients. TCA, SSRI and BDZ 
showed a similar effect in improving anxiety (symptoms and 
frequency of panic attacks) and agoraphobia, whereas SSRI 
and TCA were superior to BDZ in alleviating depression.
Since the efﬁ  cacy of all four classes of medications are 
roughly comparable, the criteria for choosing medication 
for PD patients mainly depend on considerations of adverse 
side effects (Table 3). Therefore, all the available guidelines  
recommend an SSRI compound as a ﬁ  rst choice drug for the 
treatment of PD, given the beneﬁ  cial side-effect proﬁ  le of 
this class of drugs.
Advantages and disadvantages
of different classes of drugs
SSRI
Six SSRIs are now available: citalopram. es-citalopram, 
fluoxetine, fluvoxamine, paroxetine and sertraline. No 
evidence suggests a differential efﬁ  cacy within the SSRI 
class, whereas differences exist in side-effects proﬁ  les, drug 
interaction and half-life (Table 4).
Advantages. The SSRI, compared to TCA compounds, 
are characterized by:
1.    a low afﬁ  nity for the muscarinic, α1-adrenergic and his-
taminergic receptors and therefore rarely induce blurred 
vision, dry mouth, increased heart rate, constipation, 
urinary hesitancy, orthostatic hypotension, sedation and 
weight gain;
Table 2  Advantages and disadvantages of pharmacotherapy 
and cognitive-behavior therapy (CBT) in the treatment of panic 
disorder
 Pharmacotherapy  CBT
Side-effects  ++ 0
Rapid onset of action  ++*  +
Efﬁ  cacy on more severe panic   
attacks and anticipatory anxiety  ++ +
Efﬁ  cacy on phobic avoidance  +  ++
Efﬁ  cacy on severe depression   ++§  +
Persistence of effect after   
stopping treatment  0  +
Use in primary care setting  ++ 0
Used by experienced therapist    +  ++
Need to perform “homework”   
or to confront feared situations  0  ++
Note:*Particularly benzodiazepines or §antidepressants.Neuropsychiatric Disease and Treatment 2008:4(1) 97
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2.    a safety for serious cardiac effects (Roose and Miyazaki 
2005);
3.    a low risk after an overdose (Barbey and Roose 1998).
Moreover, SSRIs are not associated with tolerance or 
physical dependence even though a withdrawal syndrome 
has been observed when an SSRI is abruptly discontinued 
(see below).
Finally, SSRIs should be preferred in PD patients with 
obsessive-compulsive disorder or in patients suffering from 
other anxiety disorders (Ballanger et al 1998). Given the 
beneﬁ  cial side-effect proﬁ  le, the use of SSRIs has been 
expected to reduce the attrition rate. A meta-analysis of 
43 studies (Bakker et al 2002) showed that the rate of 
drop-out was lower in patients treated with SSRI (18% 
out of 1059) than in patients receiving TCA (31% out of 
1308). The authors concluded that the lower drop-out rate 
in SSRI studies is most probably due to the fact that there 
are fewer side effects which induce patients to abandon 
the treatment (even though other reasons may contribute 
to the discontinuation of pharmacotherapy). However, a 
recent meta-analysis (Mitte 2005) found a similar drop-out 
rate (23%) in patients treated with an SSRI or a TCA, with 
side effects being the major reason (11%) for abandoning 
pharmacotherapy. This result conﬁ  rmed the data of the two 
previous meta-analyses conducted by Otto et al (2001) and 
by RANZCP (2003). Therefore, the use of an SSRI does 
not seem to be associated with a signiﬁ  cant reduction of the 
discontinuation of treatment compared to a TCA, although 
the SSRIs side-effect proﬁ  le should increase the tolerability. 
This ﬁ  nding points out the need to properly manage the side 
effects of SSRIs.
Disadvantages. The increased serotonergic activity 
induced by SSRIs is the cause of side effects such as anxiety, 
agitation, insomnia, tremors, nausea, anorexia, headache and 
sexual dysfunction. Since side effects occur early in treatment, 
before the therapeutic effect, and many PD patients are hyper-
vigilant regarding SSRI side effects, all strategies that minimize 
them, such as a low starting dose and a short-term co-adminis-
tration of benzodiazepines are warranted (see below).
Some SSRIs (ﬂ  uoxetine, ﬂ  uovoxamine and paroxetine) 
exert an inhibitory effect on the cytochrome P450 enzymatic 
system (particularly the isoenzymes 1A2, 2C9, 2D6 and 3A4) 
(Greenblatt et al 1998); therefore these compounds are associ-
ated with potential harmful drug interactions (ie, β-blockers, 
some BDZ).
Moreover, even though SSRI administration is not 
associated with physical dependence, an abrupt discontinuation 
of the drug may induce a withdrawal syndrome (Zajecka 
et al 1997; Warner et al 2006). This syndrome is more likely to 
Table 3  Advantages and disadvantages of the different classes 
of drugs commonly used in the treatment of panic disorder 
 SSRI  TCA  BDZ
Rapidity of effect   +  +  +++
Antidepressant efﬁ  cacy  +++  +++ 0
Efﬁ  cacy in anxiety comorbidity   +++  +++ 0
Sedation 0  +/++  ++
Cognitive impairment  0  +  ++
Anticholinergic effects  0  ++ 0
Orthostatic hypotension  0  ++ 0
Hyperstimulation   ++  + 0
Nausea   ++ 0  0
Weight gain   0/+  ++ 0
Sexual dysfunction   ++  + 0
Physical dependence  0  0  ++
Discontinuation symptoms  +  +  +++
Risk of abuse   0  0  ++
Cardiovascular effects  0  ++ 0
Safety in overdose   0  ++ 0
Drug interaction   0/++ 0  0
Table 4  Differences among the SSRI medications 
  Citalopram  Escitalopram   Fluoxetina   Fluvoxamina  Paroxetina  Sertraline
Anticholinergic effects   0  0  0/+ 0  0/+ 0
Sedation   0/+ 0  0  0/+ 0/+ 0
Insomnia 0/+  +  + 0/+  +  +
Orthostatic  hypotension  0 0  0  0  0 0
Hyperstimulation   +  +  ++  +  ++  +
Nausea   +  +  +  +  +  +
Weight gain   0/+ 0  0  0  + 0/+
Sexual dysfunction   +  +  +  +  ++  +
Discontinuation symptoms  +  + 0/+  +  ++  +
Cardiovascular  effects  0 0  0  0  0 0
Safety in overdose   0/+ 0/+ 0/+ 0/+ 0/+ 0/+
Half-life (longer than 24 h)  +  +  +++ 0  0  +
Inhibition cytochrome P450   0  0/+  ++  ++  + 0Neuropsychiatric Disease and Treatment 2008:4(1) 98
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affect patients treated for several months with a short half-life 
compound, and after a short period of tapering (a few days to 
few weeks). The withdrawal syndrome begins a few days after 
discontinuation and is characterized by dizziness, incoordina-
tion, headache, irritability, nausea and insomnia, and tends to 
resolve spontaneously within 1–2 weeks.
TCA
Imipramine was the ﬁ  rst drug used in the treatment of PD 
(Klein 1964) and along with clomipramine has been the 
most studied TCA compound in the pharmacotherapy of 
PD (Bandelow et al 2002, Pollack, Allgulander et al 2003).
Advantages. TCA do not offer major advantages 
compared to SSRI compounds, while they possess more 
disadvantages than the latter class of medications.
Disadvantages. The use of TCA, compared to SSRI, is 
associated with less tolerability and safety, because TCAs 
can induce several side effects due to their antagonistic effect 
on muscarinic, α1-adrenergic and histaminergic receptors, 
their effect on cardiac rhythm, and possible harmful 
consequences after overdose in suicide attempts (Table 3). 
Moreover, TCAs can induce, more frequently than SSRIs, 
sweating, weight gain and cognitive disturbances. Finally, 
like SSRIs, a withdrawal syndrome can occur after an abrupt 
discontinuation of TCAs (Warner et al 2006).
MAOI
Irreversible MAOI (phenelzine or tranylcypromine) are 
generally reserved for patients who do not respond to other 
treatments, because of their serious side-effects (particularly 
hypertensive crisis), the harmful consequences in association 
with other drugs that increase monoamines (sympathomimetic 
and serotonergic compounds) and the need for dietary restric-
tion (tyramine rich foods increase the risk of hypertension) 
(Riederer et al 2004). Therefore, irreversible MAOI are 
considered second-line compounds, used by experienced 
psychiatrist (APA 1998; ICGDA 1998, Bandelow et al 2002; 
CPA 2006).
The data about the efﬁ  cacy of the reversible MAOI 
meclobemibe are inconsistent and it should be used as third-
line drug (Bandelow et al 2002; CPA 2006).
Benzodiazepines
The high-potency BDZ (such as, alprazolam, clonazepam, 
lorazepam) are an effective medication in the treatment of 
PD (Susman and Klee 2005).
Advantages. In the past decade, BDZ remained one of the 
most prescribed medications for the treatment of PD. In fact, 
BDZ was the only treatment used during a follow-up period 
of 10 years in more than one third of PD patients (Bruce et al 
2003). The rapid onset of action, the high tollerability and 
the high patient acceptance are probably the reasons why 
BDZ are so often used.
However, the use of these drugs presents some disad-
vantages compared to the prescription of other effective 
medications (Table 3).
Disadvantages. On the one hand, BDZ is less effective 
than TCA or SSRI in treating depression associated with 
PD (Mitte 2005), and, on the other hand, side effects, such 
as sedation, somnolence, drowsiness, cognitive impairment, 
impairment of motor coordination, and the risk of developing 
tolerance and dependence are limitations for the use of BDZ 
(Susman and Klee 2005).
A withdrawal syndrome (Schweizer and Rickels 1998) 
may appear even after short-term administration of BDZ 
(less than 4 months) and its severity depends on the dose, 
half life, potency of the drug used, duration of the treatment 
and the length of the taper period (2–3 weeks recommended 
after 2 months of treatment). Moreover, PD patients may 
have difﬁ  culties to withdraw from BDZ, probably due to the 
reappearance of panic attacks triggered by withdrawal symp-
toms, particularly during a too short period of tapering.
Finally, abuse of BDZ may be found in patients with a 
history of alcohol or substance abuse, in patients with per-
sonality disorders or in patients who use BDZ and alcohol as 
self-medication. Therefore, in these patients, the use of BDZ 
should be evaluated with caution and, if possible, avoided.
For these reasons, the available guidelines do not recom-
mended BDZ as the drug of ﬁ  rst choice in the treatment of PD.
When recommending the use of a BDZ. The APA 
(1998) guidelines recommend the combination of SSRI and 
BDZ in the ﬁ  rst weeks of treatment. This recommendation 
is justiﬁ  ed by two clinical observations:
1.    some PD patients are very sensitive to the “activation” 
side effect of SSRI medications and anxiety, agitation, 
insomnia may appear or increase after administration 
of the antidepressant, inducing patients to discontinue 
treatment because medication worsens his or her symp-
toms;
2.    an SSRI compound takes time (4–6 weeks) to become 
effective.
Therefore, the co-administration of BDZ in the first 
weeks of treatment may alleviate the “activation” induced 
by the SSRI and reduce severity and frequency of panic 
attacks, anticipatory anxiety and/or insomnia (particularly in 
patients with nocturnal panic attacks) before the SSRI become 
effective. The co-administration of BDZ is particularly useful Neuropsychiatric Disease and Treatment 2008:4(1) 99
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in patients for whom a very rapid control of symptoms is 
critical.
A recent study (Goddard et al 2001) conﬁ  rms the APA 
guideline recommendation. This study evaluated whether 
the improvement of panic symptoms was more promptly 
observed in patients treated with a combination of clon-
azepam (0.5 mg three times a day) with sertraline than in 
patients treated with sertraline and placebo. The response 
rate (deﬁ  ned as a 50% reduction of the baseline severity) was 
higher in patients who received the clonazepam-sertraline 
association than in those who received the placebo-sertraline 
co-treatment, both after one and three weeks of therapy (41% 
vs 4% and 63% vs 32%, respectively). Similar results were 
obtained with a clonazepam-paroxetine combination treat-
ment which induced a more rapid response than with the 
SSRI alone (Pollack, Simon et al 2003).
Therefore, an initial combined treatment followed by 
BDZ tapering after a few weeks may provide early beneﬁ  t 
while avoiding the potential adverse consequences of long-
term BDZ use.
Many patients use BDZ “as needed”, prior to the exposure 
to fear situations. An infrequent as-needed use, such as once 
a week, is not a matter of concern, whereas a more frequent 
use is not recommended (Zamorski and Albucher 2002).
Other effective drugs
In a recent study (Bradwejn et al 2005), the extended-release 
form of venlafaxine (a Serotonin Noradrenergic Reuptake 
Inhibitor compound) was found to be superior to placebo 
in reducing the frequency and severity of panic attacks, 
anticipatory anxiety and phobic avoidance (even though the 
panic free status was not increased by the compound).
Medications such as trazodone, nefazodone, mirtazapina, 
reboxetine are recommended (RANZCP, World Federation of 
Societies of Biological Psychiatry [WFSBP], APA, BPA and 
CPA guidelines) as second choice drugs because there are only 
limited data about their efﬁ  cacy in the treatment of PD.
Ineffective drugs
The RANZCP, WFSBP, APA, WCA, BPA and CPA guide-
lines do not recommend the use of medications such as 
buspirone, β-blocker propanolol, clonidine, inositol, antihis-
tamines in the treatment of PD, because they are not more 
effective than placebo.
How to start medication
A low dose is recommended at the beginning of treatment 
(Table 5) to minimize the onset and severity of side-effects 
(APA 1998; Ballenger et al 1998; Baldwin et al 2005). The 
dose should then be slowly titrated upward to reach the 
recommended effective dose (Table 5).
In the ﬁ  rst weeks (4–8) of treatment with a SRRI or 
TCA compound, a concomitant administration of BDZ 
may be useful to improve clinical condition or to reduce the 
“activation” side-effects of SRRIs and TCA.
How to manage side-effects
Patients should be informed about the frequency and the time 
of onset of side-effects, reassured about the safety proﬁ  le of 
the medications (side-effects are troublesome but rarely have 
harmful physical consequences), and about the decrease of 
their severity as treatment is continued (the side-effects are 
usually short-lived).
A common mistake is to begin with a dose that is too high. 
This increases the risk of onset of side-effects. Therefore, the 
treatment strategy “start low” and “go slow” improves the 
tolerability of medication and reduces the discontinuation of 
treatment because of troubling side-effects.
The persistence of side-effects may be attenuated after 
switching to a compound of a different class. The intra-class 
switch is usually not beneﬁ  cial in reducing side-effects 
characteristic of a particular class. However, switching to 
a different SSRI drug may at times be a useful treatment 
strategy in patients who do not tolerate side-effect despite 
of partial response (ICGDA 1998; Zamorski and Albucher 
2002).
Moreover, an adjunctive therapy, instead of changing 
an effective medication, might be prescribed to counteract 
intolerable or persistently severe side-effects. That is, BDZ 
to manage agitation, anxiety and insomnia; a 5HT3 receptor 
Table 5  Doses of effective medication in the treatment of panic 
disorder
 mg/day
 Starting  Therapeutic
 dose  dose
Citalopram   10  20–60  Once a day
Escitalopram  5  10–30  Once a day
Fluoxetine   10  20–60  Once a day
Fluvoxamine  25  100–300  Bis intra day 
Paroxetine  10  20–60  Once a day
Sertaline  25  50–200  Once a day
Clomipramine  25  75–250  Once a day
Imipramine  25  75–300  Once a day
Alprazolam   0.75  2–9  Three times a day 
Clonazepam   0.75  1.5–4.5  Three times a day
Lorazepam  1  2–7.5  Three times a dayNeuropsychiatric Disease and Treatment 2008:4(1) 100
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antagonist (low dose of mirtazapine) to reduce nausea, or 
a 5HT2 receptor antagonist (low dose of mirtazapine or 
nefazodone) for sexual dysfunction (Mathew et al 2001; 
Zamorski and Albucher 2002).
How to manage non-response
Deﬁ  nition of non-response
The outcome of successful treatment should be a stable full 
remission of all PD symptoms, including depression. Despite 
progress in the treatment of PD, a signiﬁ  cant number of 
patients continue to suffer from debilitating symptoms, such 
as panic attacks, phobic avoidance or anticipatory anxiety. 
A large number of patients do not respond to standard 
ﬁ  rst-line treatments, since 45% of patients treated with a 
SSRI in controlled trials failed to achieve a panic free status 
(Otto et al 2001) and about 40% of patients were resistant to 
the combination of medication and CBT (Barlow et al 2000). 
Therefore, the management of the resistance to treatment in 
PD is a frequent problem in clinical practice.
However, before deﬁ  ning a patient as treatment-resistant, 
the adequacy of treatment should be assessed. In fact, the 
major reasons for treatment failure can be:
1.    the use of ineffective treatments: ie, one study observed 
that only 39% of PD patients received a treatment with 
effective medications or CBT (Taylor et al 1989);
2.    the use of inadequate treatment in terms of dose and 
duration: a large proportion (47%–60%) of PD patients 
received such a treatment (Yonkers et al 1996; Cowley 
et al 1997);
3.   medication intolerance which limits the dose of drugs: ie, 
intolerable side-effects were the reason for discontinuing 
medication in 27% of PD patients in the study of Cowley 
et al (1997).
Aside from the aforementioned reasons for treatment 
failure, only one fourth of PD patients reported a lack of 
beneﬁ  t after medication (Cowley et al 1997). Therefore, 
“true” resistance to treatment should only involve a minor-
ity of PD patients, when an effective medication is used, 
the initial dose is low and is slowly increased, and the 
dose and the length of treatment (see below) are adequate. 
Obviously, the rate of patients showing a non-response to 
treatment depends on its deﬁ  nition: ie, the rate of response 
decreases when the outcome of treatment is the achievement 
of a stable complete remission of panic attacks (including 
limited-symptom attacks), anticipatory anxiety, panic-
related phobias, disabilities and depression (Ballenger et 
1998). The use of the abovementioned criteria is associ-
ated with a remission rate of 46% in patients treated with a 
recommended medication for one year in clinical practice 
(Marchesi et al 2006a).
How much time should one wait before 
changing an ineffective treatment?
It is generally accepted that a response to medication does 
not occur for at least 4 weeks, and some patients do not 
experience a full response for 8–12 weeks. Therefore, 
an adequate treatment requires 8 to 12 weeks to obtain a 
clinically signiﬁ  cant improvement.
There is no controlled data to indicate when the treatment 
should be changed in patients who do not show improvement 
after pharmacotherapy. WFSBP guidelines (Bandelow et al 
2002) suggest that medication should be changed in patients 
who do not respond after four to six weeks of treatment with 
a ﬁ  rst-choice drug at an adequate dose, whereas if a partial 
response occurs in the same period of time another four to 
six weeks of therapy may be required to achieve response. 
Other guidelines (APA 1998; ICGDA 1998; NICE 2004) 
suggest that eight to twelve weeks should elapse before 
changing medication, administered at an adequate dose, when 
a signiﬁ  cant improvement does not occur.
Nevertheless, clinicians are urged by the patients and 
their families to change ineffective treatment after the ﬁ  rst 
few weeks of therapy without further delay. In a survey 
of psychiatrists (Scott et al 1999), 78% of the participants 
claimed that they would intervene on the treatment regimen 
when symptom improvement was not observed after 6 weeks 
of administration of a SSRI compound.
Predictors of nonresponse
After ruling out that the PD diagnosis is incorrect or due to 
a general medical condition, the patient is not compliant and 
the concomitant medications do not have a negative effect on 
antipanic drugs (ie, pharmacokinetic interaction) (Mathew 
et al 2001; Bandelow et al 2002), the clinician should evalu-
ate the presence of all the factors known to negatively affect 
response to pharmacological treatment. In fact, predictors of 
non-response to medications in PD patients are consistently 
identiﬁ  ed as: younger age at onset, longer duration of illness, 
higher pre-treatment severity, particularly of phobic avoid-
ance, comorbid major depression, particularly the recurrent 
form, comorbid anxiety disorders and comorbid personality 
disorders (Slaap and den Boer 2001, Marchesi et al 2006a, 
2006b; Marchesi, De Panﬁ  lis et al 2006; Marchesi et al 2007). 
In PD patients presenting such conditions, the treatment 
should be continuously monitored and a long-term duration 
should be planned.Neuropsychiatric Disease and Treatment 2008:4(1) 101
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Strategies to manage non-response
The management of patients refractory to medication is 
not an easy problem to solve in clinical practice because 
there are no proven effective strategies due to the a paucity 
of studies that have investigated this topic. This is the reason 
why some guidelines (RANZCP, APA, WCA) do not include 
any speciﬁ  c section referring to the management of treatment 
resistance.
Nevertheless, clinical experience and preliminary reports 
suggest some strategies to manage resistance to drug.
Pharmacological strategies
With the exception of one small placebo-controlled study in 
which pindolol (2.5 mg TID) demonstrated an augmenting 
effect in ﬂ  uoxetine (20 mg/day)-resistant panic patients 
(Hirschmann et al 2000), no placebo-controlled studies have 
yet been done to validate the effectiveness of switching 
compounds within or between classes or of augmenting a 
drug with a compound of another class.
However, in treatment resistant patients, different strate-
gies can be suggested (Mathew et al 2001; Bandelow et al 
2002):
1.    an augmentation with a compound belonging to another 
class of drug (TCA, BDZ, pindolol);
2.  a switch to MAOI;
3.    a use of drugs, investigated in preliminary studies, such 
as venlafaxine, mirtazapine, nefazodone, reboxetine or 
valproate.
A combination of an SSRI with imipramine or clomip-
ramine (recommended by the ICGDA, WFSBP, NICE and 
CPA guidelines) requires careful monitoring because some 
SSRIs increase TCA plasma levels through inhibition of 
cytochrome P450.
An augmentation with a BDZ (recommended by ICGDA, 
WFSBP and CPA guidelines) may offer some advantage in 
patients resistant to an adequate trial with an SSRI or TCA, 
particularly in those with severe anxiety and insomnia. How-
ever, this combination is problematic in long-term treatment, 
mainly because of the difﬁ  culty of discontinuing BDZ, and in 
patients with substance addiction who may abuse BDZ.
A switch to a MAOI (recommended by ICGDA, WFSBP 
and CPA guidelines) should be carefully monitored, because 
of their serious side-effects, the harmful consequences in 
association with other drugs that increase monoamines and 
the need for dietary restriction (Riederer et al 2004).
A switch from an antidepressant to valproate, or some-
times an augmentation with valproate, may represent an 
effective treatment strategy in PD patients refractory to 
ﬁ  rst-line medication because of a bipolar disorder or “mood 
instability”, whereas the effectiveness of other mood-
stabilizers (lithium, carbamazepine, gabapentin, lamotrigine, 
topiramate) in refractory PD is inconsistent or unproven 
(Mathew et al 2001; Bandelow et al 2002).
Recently, a few small open label trials (Holliﬁ  eld et al 
2005; Sepede et al 2006; Simon et al 2006), suggest that a 
second generation antipsychotic (olanzapine and risperidone) 
may be successfully used in patients with refractory PD. 
However, the limitations of the studies (small number of 
patients studied, open label design) did not allow for the 
drawing of conclusions regarding the effectiveness of a 
second generation antipsychotic in the treatment of refractory 
PD, and the available guidelines do not recommend the use 
of this type of medication in the treatment of PD.
Psychological strategies
In the last decade, CBT is recommended (APA, NICE, BPA 
and CPA guidelines) in patients who show partial or no 
response to medications. Recent studies demonstrated that 
adding CBT improved the outcome in patients who failed 
to respond to an adequate trial of pharmacotherapy (Heldt 
et al 2003) and maintained a panic free status over a one 
year follow-up period in two thirds of patients resistant to 
medications (Heldt et al 2006).
Moreover, psychological therapy is probably beneﬁ  cial 
for symptom stabilization in PD patients with personality 
disorders or with extensive psychological conﬂ  icts (APA 
1998; Mathew et al 2001).
In order to manage patients who are refractory to 
medications, CBT seems to be the strategy preferred by psy-
chiatrists: in a survey (Scott et al 1999), the addition of CBT 
in non-responders to a trial of an SSRI was the most popular 
choice (34% of psychiatrists interviewed), preferred to add a 
BDZ (27%) and to increase the dose of SSRI (26%).
How long should the treatment last?
Even though the optimal length of pharmacotherapy 
is unclear, there is evidence that antipanic medication 
response continues while the patient is taking medication 
and that relapse is common after discontinuation of drugs 
(Ballenger 1999). To maintain full remission and to decrease 
the risk of relapse after stopping medication, a longer 
period of maintenance treatment (12–24 months) has been 
recommended by the ICGDA (Ballenger et al 1998).
Nonetheless, a recent study (Mavissakalian and Perel 
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who discontinued imipramine 6 or 12–30 months after 
achieving a 50% improvement of pre-treatment severity or 
a presence of mild symptoms. This result suggests that the 
maintenance of beneﬁ  t following treatment discontinuation 
may be much more inﬂ  uenced by the level of symptom 
severity before treatment discontinuation (the patients were 
again symptomatic when treatment was discontinued) than 
the duration of treatment. Such a ﬁ  nding underscores the 
importance of maximizing improvement: achieving a stable 
status of remission is needed before considering treatment 
discontinuation in order to increase the likelihood of main-
taining improvement after stopping medication. Therefore, 
the discontinuation of medication should be considered in 
patients who maintain a full remission for a long period 
(6 months recommended by NICE and BPA guidelines and 
at least 12 months recommended by APA, ICGDA, WCA 
and CPA guidelines) and are not currently experiencing a 
stressful life event.
Otherwise, ICGDA (Ballenger et al 1998) recommended 
that treatment should be continued in patients with substantial 
residual symptoms, comorbid conditions, a history of severe 
relapse or high levels of stress due to important lifestyle 
changes. Patients should be reassured regarding the fact that 
PD is a condition that often requires long-term treatment.
How to discontinue medication
Patients should be informed not to stop medication abruptly, 
without consulting their physicians, to avoid a withdrawal 
syndrome. Severe withdrawal syndrome appears particularly 
after the abrupt discontinuation of BDZ (Schweizer and 
Rickels 1998), but symptoms of discontinuation can also 
follow a tapering period of a SSRI or TCA compound that 
is too short (Warner et al 2006). Therefore, a slow tapering 
of medications (4–6 months) should be recommended by 
ICGDA (Ballenger et al 1998).
Pharmacological treatment of PD
in special populations
Children and adolescents
Anxiety disorders are not easy to assess in children and ado-
lescents and many methodological problems can reduce the 
reliability of the data (Silverman and Ollendick 2005), par-
ticularly the results of studies investigating PD in children.
However, epidemiological studies in community samples 
suggest that panic attacks are frequently observed in chil-
dren and adolescents: panic attacks were observed in 3% of 
youths aged from 9 to 17 years (Goodwin and Gotlib 2004) 
and PD was diagnosed in 10%–12% of clinically referred 
children and adolescents (Masi et al 2000; Doerﬂ  er et al 
2006). Nevertheless, recommendations for the treatment of 
PD in youths are supported by much less evidence than in 
adults. Until now, only anecdotal reports or small studies (less 
than 20 subjects) have been published about treatment of PD 
in children and adolescents (Murphy et al 2000; Masi et al 
2006), and showed that a SSRI compound could be safely 
and effectively used.
Therefore, the use of SSRI in youths needs to be more 
consistently demonstrated by large studies using a more 
powerful methodology (double-blind, controlled treat-
ment). However, as observed in the treatment of obsessive-
compulsive disorder, the use of SSRI compounds seems 
promising in the treatment of PD in children and adolescents. 
Nevertheless, a risk associated with use of SSRI drugs in 
children and adolescents must be evaluated. A meta-analysis, 
carried out by the US FDA on 24 placebo-controlled studies 
on antidepressants (mainly used in the treatment of major 
depression and obsessive-compulsive disorder), found an 
increased risk of suicide attempts (relative risk of 1.95; CI 
95% 1.28–2.98) in subjects treated with antidepressants 
(particularly paroxetine and venlafaxine) compared with 
subjects receiving placebo (data available on website http://
www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1_
08_FDA-Hammad_ﬁ  les/frame.htm). Therefore, the use of 
antidepressants must be carefully evaluated in children and 
adolescents with PD.
Although anecdotal reports have also been published 
about the safe and effective use of BDZ in the treatment of 
children and adolescents with PD (Masi et al 2006), BDZ 
are not recommended in the treatment of these subjects to 
avoid somnolence, impairment of cognitive function and 
dependence.
Pregnant women
The prevalence of PD ranged from 1.2% to 2.0% in preg-
nant women (Ross and McLean 2006). The onset of PD 
occurs in a minority of women during pregnancy, whereas 
in most women the pregnancy can affect the course of PD. 
The available data on this topic are conﬂ  icting, due to their 
large dispersion: in fact, the rate of women or pregnancies 
with an unchanged pregravid severity of symptoms ranged 
from 18% to 80%, an increased severity from 4% to 33% 
and an improvement of symptoms in 10%–74% of cases 
(Ross and McLean 2006). However, the hypothesis that the 
pregnancy is a “well-being period” for women affected by 
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(Bandelow et al 2006) found that the panic manifestations of 
PD were signiﬁ  cantly lower during pregnancy than during a 
non-pregnancy period.
In the last decade, even though no medication recom-
mended for the treatment of PD is licensed for the adminis-
tration in pregnant women, and PD can be treated without 
medications using CBT, the use of a SSRI compound in 
pregnancy is widespread in clinical practice, as demonstrated 
by data collected by the Finnish and Swedish Medical Birth 
Registers (Malm et al 2005; Källén and Olausson 2006). In 
fact, nearly all the available SSRI compounds (at the moment 
data are not available on escitalopram) are largely used in 
pregnant women (1782 women in the Finnish Register and 
5123 women in the Swedish register), even within the ﬁ  rst 
trimester of pregnancy (1398 women in the Finnish Register 
and all the 5123 women in the Swedish register), at a time 
when the drugs may exert their possibly teratogenic effect. 
The available data show that the frequency of major mal-
formations (a malformation that severely impaired function 
or that needed a surgical correction of the affected organ) 
was similar in women treated with SSRI compounds and 
in women without such a treatment (4.2% vs 3.5% in the 
Finnish Register) and that the risk of any malformation did 
not increase in women treated with SSRI (OR 0.87; CI 95% 
0.76–1.01 in Swedish Register).
Nevertheless, in Swedish Register (Källén and Olaussoen 
2006) an excess risk of cardiac defects (mainly atrial or 
ventricular septum defects) (OR 2.22; CI 95% 1.39–3.55) 
was observed in births of women exposed to paroxetine 
(but not to other SSRI compounds) during the ﬁ  rst tri-
mester of pregnancy. This ﬁ  nding conﬁ  rms the previous 
reports (Wogelius et al 2005; the GlaxoSmithKline advi-
sory, available on web site www.gsk.ca/en/health_info/
PAXIL_PregnancyDHCPL_E-V4.pdf), which induced the 
US FDA and the Health Canada to recommend adding 
this information in the Warnings section of prescribing 
information of paroxetine. Recently, the American College 
of Obstetricians and Gynecologists (2006) recommends to 
avoid the use of paroxetine in pregnant women or in women 
planning to become pregnant.
However, a recent study (Berard et al 2006) suggests that 
only the use of paroxetine at a dose higher than 25 mg/day 
in the ﬁ  rst trimester is associated with an increased risk of 
major malformations (OR = 2.23; 95% CI = 1.19–4.17) 
or an increase in cardiac defects (OR = 3.07; 95% CI = 
1.00–9.42).
In late pregnancy, the administration of SSRI exposes 
the newborns to the following two risks:
1.    about 30% of them may present a withdrawal syndrome 
which, however, rarely is severe enough to require treat-
ment (Moses-Kolko et 2005; Sanz et al 2005);
2.   an increased risk of persistent pulmonary hypertension in 
newborns of mothers taking ﬂ  uoxetine (OR 6.1; CI 95% 
2.2–16.8) (Chambers et al 2006). However, this serious 
condition was uncommon, since about 99% of women 
exposed to this class of compound in late pregnancy did 
not deliver newborns affected by this condition.
Concerning the cognitive and behavioral effect of the 
in-utero exposure to antidepressants, the available data 
suggest that ﬂ  uoxetine, taken during pregnancy, does not 
adversely affect cognition, language development or tem-
perament of preschool and early school children. (Nulman 
et al 2002)
During pregnancy, the use of BDZ is not recommended 
(American Academy of Pediatrics 2000, Iqbal et al 2002; 
Eberhard-Gran et al 2005), because the administration of 
BDZ in the ﬁ  rst trimester increases the risk of cleft lip/palate, 
and in late pregnancy induces a withdrawal syndrome or a 
“ﬂ  oppy baby syndrome” (muscular hypotonia, low Apgar 
scores, hyperthermia, impaired response to cold) in BDZ-
dependent newborns.
In conclusion, the risk-beneﬁ  t assessment of the use of 
medication in pregnant women, particularly during the ﬁ  rst 
and third trimester of pregnancy, must be discussed with 
the woman and her family and an informed consent should 
be obtained.
Breastfeeding women
During post-partum, the frequency of PD increases compared 
to pregnancy (1.4%–3.9% of women), and a worsening of 
pregravid symptom severity more likely occurs, as observed 
in 20%–63% of women or post-partum periods (Bandelow 
et al 2006; Ross and McLean 2006).
In the post-partum period, the use of a SSRI must be 
carefully evaluated, because the newborns are exposed to 
medications through breast milk. Even though the available 
data concerning the effects of exposure of breastfeeding 
infants to a SSRI drug are reassuring, and breastfeeding 
should not be generally discouraged in women using SSRI 
(Weissman et al 2004; Berle et al 2004; Eberhard-Gran 
et al 2006), in clinical practice most women prefer to dis-
continue breastfeeding when a pharmacotherapy is needed 
to avoid a potential danger for the infant. However, when 
the mother chooses to take medication while breastfeeding, 
ﬂ  uoxetine and citalopram should not be the drugs of ﬁ  rst 
choice, because the long plasma half-life of the former and Neuropsychiatric Disease and Treatment 2008:4(1) 104
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the detectable plasma level in the newborns of the latter may 
cause adverse effects in the infants (Eberhard-Gran et al 
2006). Obviously, a non-pharmacological treatment can be 
recommended in women who chose breastfeeding and prefer 
to avoid medications.
Conclusions
The available data on the evidence-based efﬁ  cacy of the 
pharmacological treatment in PD suggest the following 
indications to clinicians:
1.    a SSRI compound is the ﬁ  rst choice medication, for the 
beneﬁ  cial side-effect proﬁ  le of this class of drugs.
2.    the medication should be started at a low dosage to pre-
vent side effects and then increased until the therapeutic 
dose is reached;
3.    in the ﬁ  rst weeks of treatment, a BDZ can be usefully 
associated to a SSRI compound to rapidly improve 
symptoms and to mitigate the “activation” side effects 
of the SSRI medication;
4.   the medication should be continued to achieve, when pos-
sible, a complete remission of symptoms and thereafter 
maintained for at least 12 months;
5.    the medication should be discontinued slowly to prevent 
the onset of a withdrawal syndrome.
In spite of the fact that the aforementioned suggestions 
are recommended by all available international guidelines, 
some clinical problems in the treatment of PD are difﬁ  cult 
to manage because of the lack of reliable data. Speciﬁ  cally, 
the management of partial-response or non-response is not 
well established because only a few studies addressed this 
topic with a rigorous methodology. Also, the treatment of PD 
in children or adolescents and in pregnant or breastfeeding 
women was only evaluated in observational studies. There-
fore, clinicians should consider all precautions when they 
are asked to treat PD in these patients.
Moreover, strategies are needed to provide effective 
care to people with PD in the general population, since 
only a minority of them receives any mental health treat-
ment.
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